On Tuesday, Biogen announced that it’s bringing back aducanumab, the Alzheimer’s drug it abandoned earlier this year. This announcement was a financial game-changer for Biogen shares (Poof–news erased 25% year-to-date drop just.like.that). And aducanumab, if approved, could be a medical game-changer for some Alzheimer patients (and their families) since new research shows that it slows cognitive decline in early-stage patients. Current treatments for Alzheimer’s only ease symptoms temporarily.

  •  Get NoPo Delivered Daily

    We hate SPAM as much as you do! Rest assured, your information stays private as per our privacy policy.